Top 200 Medicines — Special Report - PharmaLive (press release) (subscription)
The precipitous patent cliff of 2012 assaulted Big Pharma to the tune of up to $53 billion worth of prescription drug sales potentially lost to patent expirations. This time, however, the brunt is expected to be much less widespread than the 2012 impact as more than sixty percent of the sales are tied to biotechnology drugs that are not yet facing biosimilar competition in the United States and in some other... With most blockbuster biotech brands expected to continue to thrive in the near term minus significant biosimilar competition, the pharma/biotech industry is experiencing a substantial growth period. Global prescription drug sales have been projected by various industry analysts to continue growing, at nearly a five percent rate annually until 2020. Aiding the growth rate is a new wave of first-in-class blockbuster products and a recent... A total of 41 new molecular entity and new therapeutic biological products were approved by the U. S. Food and Drug Administration during 2014, the second-highest total ever (there were 53 new drug approvals by FDA in 1996). Also contributing to... Source: www.pharmalive.com
